BioSpace News Archive

Avicanna Inc. is pleased to announce the Company’s first indication-specific drug registration for Trunerox™ issued by INVIMA, the Health Authority of Colombia.

Incyte (Nasdaq:INCY) today reports 2023 fourth quarter financial results, provides 2024 financial guidance and provides a status update on the Company’s research and development portfolio.

Ocular Therapeutix, Inc. today announced that the first three subjects have been screened and received their first aflibercept injection in the Phase 3 SOL-1 clinical trial of AXPAXLI™ (axitinib intravitreal implant.

Aligos Therapeutics, Inc. today announced the appointments of Jordyn Tarazi as Vice President, Investor Relations and Corporate Communications and Nikhil Aneja as Vice President, Finance, effective immediately.

RAPT Therapeutics, Inc. today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.

Shuttle Pharmaceuticals Holdings, Inc. today announced its intent to commence a Rights Offering where it plans to raise up to $4.5 million through the distribution of subscription rights and the exercise thereof, which full rights will entitle existing SHPH stockholders to purchase from the Company units (the “Units”), with each Unit consisting of (i) one share of SHPH common stock.

Stryker (NYSE: SYK) showcases its commitment to innovation and technological advancement in Joint Replacement with the introduction of Triathlon® Hinge as well as the continued evolution of Mako SmartRobotics™ at this year’s American Academy of Orthopaedic Surgeons’ (AAOS) 2024 Annual Meeting in San Francisco.

Sudo Biosciences today announced that during January 2024, it completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund.

Verasonics, Inc. today announced the expansion of its management team with the appointments of Christian Coviello, Ph.D. as Director of Ultrasound Science, and Andrew Lundberg as Director of Hardware Engineering and Operations.

Legend Biotech Corporation will host a conference call for investors at 8:00 am ET on Monday, March 11, 2024, to review fourth-quarter and full-year 2023 results.